{
    "2019-12-29": [
        [
            {
                "time": "2019-12-23至2019-12-29",
                "original_text": "【太平洋医药】第二轮全国集采方案公布，继续推荐景气度好，行业天花板高，不受政策影响/影响较小的细分领域",
                "features": {
                    "keywords": [
                        "全国集采",
                        "政策影响",
                        "细分领域",
                        "景气度",
                        "行业天花板"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2019-12-23至2019-12-29",
                "original_text": "梳理与展望，盘点2019的“热点”与“冷门” --- 医药行业周报（2019.12.23-2019.12.29）",
                "features": {
                    "keywords": [
                        "热点",
                        "冷门",
                        "医药行业",
                        "周报"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "中信建投策略首席分析师张玉龙：2020年“牛蹄”稍慢 两类股有机会",
                "features": {
                    "keywords": [
                        "中信建投",
                        "张玉龙",
                        "2020年",
                        "投资机会"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【国盛医药张金洋团队】周观点：肝素到底周期还是成长？——兼论全球肝素产业链重构",
                "features": {
                    "keywords": [
                        "国盛医药",
                        "张金洋",
                        "肝素",
                        "周期",
                        "成长",
                        "产业链重构"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}